BlackRock Inc. - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 364 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.

Quarter-by-quarter ownership
BlackRock Inc. ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$692,131,092
+3.1%
18,118,615
-2.6%
0.02%
+11.1%
Q2 2023$671,064,060
-3.2%
18,604,493
+2.5%
0.02%
-10.0%
Q1 2023$692,990,086
-33.1%
18,145,852
-0.4%
0.02%
-37.5%
Q4 2022$1,036,474,809
+44.0%
18,215,726
+0.1%
0.03%
+33.3%
Q3 2022$719,614,000
-11.0%
18,199,633
-1.0%
0.02%
-7.7%
Q2 2022$808,782,000
+3.1%
18,381,405
-6.6%
0.03%
+23.8%
Q1 2022$784,449,000
+0.4%
19,670,225
+1.2%
0.02%
+5.0%
Q4 2021$781,676,000
-0.4%
19,439,863
+0.7%
0.02%
-9.1%
Q3 2021$784,935,000
-9.3%
19,295,380
+1.2%
0.02%
-8.3%
Q2 2021$865,808,000
+12.6%
19,066,438
+3.4%
0.02%
+4.3%
Q1 2021$768,660,000
-2.6%
18,437,478
-0.2%
0.02%
-8.0%
Q4 2020$789,337,000
+127.4%
18,481,307
+39.9%
0.02%
+92.3%
Q3 2020$347,138,000
-2.2%
13,209,235
-0.2%
0.01%
-7.1%
Q2 2020$354,786,000
+62.4%
13,233,306
+8.9%
0.01%
+27.3%
Q1 2020$218,520,000
+1.9%
12,146,804
+0.4%
0.01%
+37.5%
Q4 2019$214,477,000
+6.3%
12,096,797
-7.0%
0.01%0.0%
Q3 2019$201,701,000
-7.0%
13,004,538
+3.0%
0.01%
-11.1%
Q2 2019$216,900,000
+15.2%
12,625,128
+8.0%
0.01%
+12.5%
Q1 2019$188,292,000
+9.5%
11,695,148
-0.5%
0.01%
-11.1%
Q4 2018$171,991,000
-20.3%
11,756,120
-1.1%
0.01%0.0%
Q3 2018$215,886,000
+4.5%
11,881,526
-2.9%
0.01%
-10.0%
Q2 2018$206,530,000
-9.0%
12,242,431
+5.7%
0.01%
-9.1%
Q1 2018$226,905,000
-7.4%
11,582,668
-4.2%
0.01%
-8.3%
Q4 2017$245,025,000
+16.0%
12,094,021
-0.6%
0.01%
+9.1%
Q3 2017$211,295,000
+42.1%
12,164,375
+4.9%
0.01%
+37.5%
Q2 2017$148,652,000
+3.7%
11,595,500
+4.8%
0.01%0.0%
Q1 2017$143,374,000
+9600.5%
11,062,842
+7292.8%
0.01%
+300.0%
Q4 2016$1,478,000
+459.8%
149,643
+584.7%
0.00%
Q3 2016$264,000
+45.1%
21,856
+3.8%
0.00%
Q2 2016$182,000
+171.6%
21,061
+197.9%
0.00%
Q1 2016$67,000
+26.4%
7,070
+129.8%
0.00%
Q4 2015$53,000
+1.9%
3,077
-19.2%
0.00%
Q3 2015$52,000
-24.6%
3,809
+24.5%
0.00%
Q2 2015$69,000
+46.8%
3,060
-5.5%
0.00%
Q1 2015$47,000
+51.6%
3,2380.0%0.00%
Q4 2014$31,000
+6.9%
3,2380.0%0.00%
Q3 2014$29,000
-9.4%
3,2380.0%0.00%
Q2 2014$32,000
-22.0%
3,238
-0.5%
0.00%
Q1 2014$41,000
-12.8%
3,255
+4.3%
0.00%
Q4 2013$47,000
+30.6%
3,120
-4.3%
0.00%
Q3 2013$36,000
+38.5%
3,2600.0%0.00%
Q2 2013$26,0003,2600.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
SNYDER CAPITAL MANAGEMENT L P 4,324,232$165,185,6623.73%
Steamboat Capital Partners, LLC 196,898$7,521,5042.79%
2Xideas AG 600,799$22,950,5222.54%
BERNZOTT CAPITAL ADVISORS 171,808$6,563,0662.26%
Redwood Investments, LLC 328,459$12,547,1341.70%
Mesirow Institutional Investment Management, Inc. 380,415$14,531,8531.47%
Granite Investment Partners, LLC 856,253$32,708,8651.37%
Penn Capital Management Company, LLC 324,707$12,453,2111.28%
EFG Asset Management (North America) Corp. 137,739$5,262,3191.25%
First Light Asset Management, LLC 313,536$11,977,0751.14%
View complete list of HALOZYME THERAPEUTICS INC shareholders